Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for MRK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -5.602B
March 31, 2026 -10.21B
December 31, 2025 -11.20B
September 30, 2025 -283.00M
June 30, 2025 -770.00M
March 31, 2025 -1.487B
December 31, 2024 -1.444B
September 30, 2024 -3.845B
June 30, 2024 -1.069B
March 31, 2024 -1.376B
December 31, 2023 53.00M
September 30, 2023 -334.00M
June 30, 2023 -11.44B
March 31, 2023 -2.359B
December 31, 2022 -1.748B
September 30, 2022 -962.00M
June 30, 2022 -1.077B
March 31, 2022 -1.173B
December 31, 2021 -12.05B
September 30, 2021 -1.061B
June 30, 2021 -2.811B
March 31, 2021 -634.00M
December 31, 2020 -4.778B
September 30, 2020 -2.155B
June 30, 2020 -882.00M
Date Value
March 31, 2020 -1.628B
December 31, 2019 -763.00M
September 30, 2019 191.00M
June 30, 2019 -2.425B
March 31, 2019 368.00M
December 31, 2018 2.178B
September 30, 2018 1.66B
June 30, 2018 673.00M
March 31, 2018 -197.00M
December 31, 2017 -58.00M
September 30, 2017 671.00M
June 30, 2017 -1.127B
March 31, 2017 3.193B
December 31, 2016 -2.563B
September 30, 2016 -890.00M
June 30, 2016 -1.498B
March 31, 2016 1.741B
December 31, 2015 -617.00M
September 30, 2015 -61.00M
June 30, 2015 2.525B
March 31, 2015 -6.605B
December 31, 2014 7.204B
September 30, 2014 -3.722B
June 30, 2014 -49.00M
March 31, 2014 -3.807B

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Johnson & Johnson -1.11B
Eli Lilly & Co. -15.40B
Pfizer Inc. 2.106B
Bristol Myers Squibb Co. -1.614B
Abbott Laboratories -673.00M